32 results about "Drugs trials" patented technology

A method of evaluating and/or optimizing clinical outcomes and providing rational pharmacotherapy in an individual or animal requiring chronic drug therapy is provided.

A machine, computer program product, and computer-implemented method for performing a process of managing clinical research data by collating a plurality of clinical patient records into a database system and a process of allowing particular clinical users to access the clinical research records.

The invention discloses a drug clinical trial monitoring method and system based on the block chain, a device and a medium and relates to the technical field of the drug clinical trial. The block chain technology is introduced, test records are maintained jointly by participants in the drug trial and stored in a block chain in a chronological order through the chain structure, through use of the block chain, characteristics can be only added and are non-tamperable and deleteable, and data authenticity and validity are guaranteed; rights of subjects are better protected through the intelligentcontract technology, an informed consent is stored in the block chain in the form of an intelligent contract, during the test, the physiological data of the subjects are obtained in real time throughdocking with the medical device, once the event triggering a contract suspension clause is monitored, payment is automatically executed according to the contract terms; through the decentralized storage idea, defects including large cost of data storage space, incomplete privacy protection and weak anti-attack ability existing in a centralized drug test management system in the prior art are solved.

Accurate self report strategies, biological state markers, combinations of alternative biomarkers, and combinations of biomarkers and self reports capable of monitoring alcohol consumption with a high sensitivity and specificity over a broad time spectrum are disclosed.

In particular, the use of ethyl sulfate (monoethylsulfate, molecular weight 126 g/mol, C₂H₅SO₄H) to elucidate ethanol intake is described in the context of screening monitoring in various settings, e.g. a) after liver transplantation b) methadone maintenance patients with hepatitis C and comorbid excessive alcohol use c) underage drinking d) rehabilitation programs for alcoholics motivational feedback to improve knowledge on drinking patterns differentiating moderate/social drinking from problematic/harmful drinking differential diagnosis (e.g. elevated transaminases) evaluating treatment programs and drug trials elucidating the role of neuropsychological impairment following alcoholisation (i.e. hangover state) which plays a major role in accidents, disclosing recent drinking in social drinkers in risky situations (driving, workplaces, pregnancy (fetal alcohol syndrome (FAS)), and general monitoring.

The invention discloses an application of clostridium butyrate in a preparation for prevention and treatment or adjuvant therapy of hyperglycemia and belongs to the technical field of prevention and treatment of diabetes. According to the application, during the prevention and treatment or adjuvant therapy of the hyperglycemia, butyric acid is produced in an intestinal tract, meanwhile, florae of the intestinal tract are changed, signals are sent to an ileum, a liver, a pancreatic gland and a brain by a portal vein blood sugar sensor, the ileum is promoted to secrete (GLP-1) glucagon-like peptide-1, the gluconeogenesis of the liver is lowered, pancreatic beta cells are protected, the secretion of insulin of the pancreatic gland is promoted, and thus, the action of reducing blood sugar is exerted. The clostridium butyrate is a medicine which has been proven by clinical drug trials and can be directly taken orally.

A system and method for planning, forecasting, administering, and managing the logistics of the supply chain for clinical trials for the products of pharmaceutical and biotechnology concerns includes providing functionality that eliminates the need to understand and directly manage the complexities of conducting a clinical trial by way of an integrated system of functional modules that provide capabilities in the areas of supply chain planning and forecasting (including logistics, budgeting, labeling, accountability, and destruction), recruitment planning and forecasting, utilization monitoring and tracking, and patient assignment and randomization, as well as simulating the conduct of such a clinical drug trial.

The invention provides an implementation method of a subject payment system for a drug test in clinical research. The subject payment system comprises a Web terminal and a mobile terminal subject payment form page. The method comprises the following steps: packaging parts of a design form to obtain JSON data; forming a basic part column from the data corresponding to the part; performing second-level packaging on the elements in the basic part column to form a design part in response to clicking and moving operations; monitoring the part subjected to the second-level packaging in the form design area; performing data binding and rendering on the part; arranging the parts; displaying a configuration bar; receiving an operation of a Web end; transmitting data corresponding to the designed form to a server side; requesting data of a subject payment form page from the mobile terminal, wherein elements of the form page are defined by a first form style based on a Web terminal page; and converting the page defined by the first form style into a page defined by a second form style based on the mobile terminal at the mobile terminal.

The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); a method for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can provide marked neuroprotective therapy for living subjects with motoneuron diseases including delay in symptoms and prolongation of survival; and the discovery that monitoring of neuronal microtubule dynamics in subjects with motoneuron diseases, in response to therapeutic interventions, allows diagnostic monitoring for optimization of therapeutic regimen and strategy for individual subjects or for drug trials.

The invention relates to an information reminding method and system and computer equipment. The information reminding method comprises the steps: receiving the login information of a subject; according to the login information, searching item information corresponding to the subject, wherein the item information comprises reminding information of preset time; and sending the reminding informationto the subject in the preset time. According to the method and the device, the problem that an existing hospital information system cannot provide effective support for clinical drug tests and subjectmanagement, so that the subjects miss project reservation plans, and AE sending or data inaccuracy is caused is solved.

The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); methods for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can improve MT-mediated transport of “synaptic vesicle cargo” molecules along and through axons; the discovery that such modulation of altered microtubule dynamics and improvement in MT-transport of molecules along axons can provide marked neuroprotective therapy for living subjects with motoneuron diseases, including delay in symptoms and prolongation of survival; and the discovery that monitoring of neuronal microtubule dynamics in response to therapeutic interventions in subjects with motoneuron diseases, allows diagnostic monitoring, to optimize therapeutic regimens and treatment strategies in individual subjects or in drug trials. The monitoring involves measuring isotope enrichment in secreted synaptic vesicle cargo molecules.

The invention discloses a drug alert system access system and method based on artificial intelligence, and the system comprises a drug query module which is used for querying the types of drugs to be accessed; the patient information acquisition module is used for acquiring various associated information of the drug trial patients aiming at the to-be-accessed drug types in the drug query module; the verification and verification module is used for carrying out logic verification on the associated information of the drug test patients of the to-be-accessed drug types obtained in the patient information acquisition module, judging whether suspicious information exists in the associated information or not, and carrying out manual verification on the suspicious information; and the medicine alert report generation module is used for summarizing the associated information of the medicine test patients of the to-be-accessed medicine types passing the verification and verification in the verification and verification module to obtain the medicine alert reports corresponding to the medicine test patients, and judging the priorities of the medicine alert reports according to the contents of the medicine alert reports.

The invention discloses a matching method and device for clinical drug test patients and computer equipment, relates to the technical field of computers, and can solve the technical problems that the workload is large, the efficiency is relatively low, and error accumulation and information loss are easily caused when the clinical drug test patients are matched at present. The method comprises the steps that patient information of a test patient and medical test queuing condition information are acquired, the patient information comprises first numerical value type information and doctor seeing information, and the medical test queuing condition information comprises second numerical value type information and description information; performing numerical value matching on the first numerical value type information and the second numerical value type information to obtain a first matching result; preprocessing the doctor-seeing information and the description information, and performing embedded matching on the preprocessed doctor-seeing information and description information to obtain a second matching result; and generating a final matching result of the test patient and the medicine test according to the first matching result and the second matching result.

The invention relates to a hot-melt compression type blood collection tube recoverer for clinical drug tests. A partition plate is arranged in the middle of a shell and divides the shell into an upper cavity and a lower cavity, a preheating groove is formed in the upper cavity and communicates with a placement opening and the lower cavity, and therefore a blood collection tube is guided to fall onto a drawer type bearing mechanism arranged in the lower cavity; and the drawer type bearing mechanism has a heating function and is matched with a hot-pressing mechanism, and hot-melt compression of the blood collection tube in the drawer type bearing mechanism is achieved. The disposable blood collection tube can be preheated and then heated to be softened, the disposable blood collection tube is matched with an upper pressing plate for hot pressing to form a whole body for storage, the occupied area is saved, in the process, residual blood in the disposable blood collection tube can be evaporated to dryness, and bacterium breeding and peculiar smell generation are prevented; and more importantly, a plate damage type treatment mode is formed after hot-melt compression, and the disposable blood collection tube can be effectively prevented from flowing into the market again.

The invention discloses a visual chart suitable for a clinical test and a use method of the visual chart. The optotype size, the geometric increase rate, the line number, the optotype spacing and the line spacing of the visual chart all adopt international standards, and the innovation point is that each row of optotypes of an optometry chart (chart R) is composed of a C optotype with a gap and four rolling E optotypes. Each of the two optotypes has upward, downward, leftward and rightward orientations. The standardized operation specifications of the ETDRS visual chart and ETDRS optometry are gold standards of international clinical drug trials. On the basis of the rolling E optotypes commonly used by Chinese people, the combination of the two optotypes is provided in the newly designed optometry chart, namely, one C optotype exists in each row of rolling E optotypes, so that the requirements of identification and expression habits of Chinese people are better met during use, meanwhile, qualitative and quantitative measurement and verification of the axial direction and the degree of astigmatism of a subject can be performed, and the vision detection efficiency and accuracy can be improved.

The invention discloses a visual identification screening method for adverse events of a drug test. The method comprises the following steps: acquiring baseline period data and test period data of each test object from an EDC database; performing validity verification on the acquired baseline period data and the test period data, and screening out a test object to be identified; performing identification processing on the baseline period data and the test period data of each to-be-identified test object, and outputting visual data convenient to identify; and popping up and displaying the visual data is popped up and displayed, so that visual review and check are facilitated. According to the visual identification screening method, complete and effective test objects of baseline period dataand test period data can be screened out, so that manual integrity and effectiveness check is avoided, and the screening efficiency and accuracy of adverse events can be effectively improved; and meanwhile, the test object data after validity verification can be identified and sorted, so that the visual examination of personnel is facilitated, and the discrimination efficiency is further improved.

The present disclosure provides an oral data collection device comprising a mouthguard and at least two sensors, a medical analytics system comprising the device, and methods of using the device and system to provide a personalized treatment protocol, stage a health condition, measure a response to therapy, phenotype for selection to participate in drug trials, measure stability of an anatomical structure, or predict a rate of change of a health condition in a subject in need thereof.

The invention discloses a drug test data control method and system, and the system comprises: a quality control link processing module which is used for inputting control template data based on a quality control point of a drug clinical test; a data verification center module which is used for receiving the control template data of the quality control link processing module and converting non-standard data in the control template data into uniform structural data; a project center module which is used for summarizing clinical test project information and serves as a unified output port of the clinical test project information; a data storage center module which is used for storing effective data in clinical test items; and a system auditing module which is used for performing calculation based on the effective data of the clinical test project to obtain a project quality control content item. According to the scheme, full-process monitoring and processing of the drug test data are achieved, the error rate in the processes of data recording, screening and the like is effectively reduced, the carding and storage efficiency of the data is greatly improved, and the quality and effectiveness of basic data are improved.